Inovio Pharmaceuticals has been granted a patent for an electroporation device with a needle array that includes an adjustable auto-lock assembly. The device allows for controlled movement of the needle array between rest and actuated positions, enhancing precision and safety during electroporation procedures. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Electroporation device with adjustable needle array auto-lock assembly
A recently granted patent (Publication Number: US11883653B2) discloses a needle array for an electroporation device. The device includes a body with a locking surface and a shroud that can move between rest and actuated positions. An auto-lock mechanism, adjustable between locked and unlocked configurations, ensures the shroud's movement is controlled. The body also features electrodes and hypodermic needles, with the electrodes extending outside the shroud in the actuated positions and the needles positioned within the shroud in the rest position. Additionally, the device includes a receiver for a drug cartridge, with a drive assembly for injecting the drug into a patient and various locking mechanisms to secure the components in place.
The needle array's design allows for precise control and movement of the shroud, electrodes, and hypodermic needles, ensuring accurate and efficient drug delivery to patients. The inclusion of locking mechanisms and an auto-lock feature adds an extra layer of safety and control to the device, preventing accidental movements or dislodging of components during use. Overall, the patented needle array offers a sophisticated and reliable solution for electroporation procedures, combining functionality with safety measures to enhance the user experience and treatment outcomes.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
